In conclusion, the GCIG CA125 criteria overestimate a tumour response measured by WHO criteria in monitoring the efficacy of topotecan or paclitaxel–carboplatin when used as second-line regimens in patients with epithelial ovarian carcinoma. The gene discussed is MUC16; the disease is neoplasm.